258 related articles for article (PubMed ID: 31783769)
1. Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1.
Forlani G; Shallak M; Ramia E; Tedeschi A; Accolla RS
Retrovirology; 2019 Nov; 16(1):34. PubMed ID: 31783769
[TBL] [Abstract][Full Text] [Related]
2. The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-κB by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein.
Forlani G; Abdallah R; Accolla RS; Tosi G
J Virol; 2016 Jan; 90(7):3708-21. PubMed ID: 26792751
[TBL] [Abstract][Full Text] [Related]
3. The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators.
Forlani G; Abdallah R; Accolla RS; Tosi G
Front Microbiol; 2013; 4():234. PubMed ID: 23986750
[TBL] [Abstract][Full Text] [Related]
4. Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.
Tosi G; Forlani G; Andresen V; Turci M; Bertazzoni U; Franchini G; Poli G; Accolla RS
J Virol; 2011 Oct; 85(20):10719-29. PubMed ID: 21813598
[TBL] [Abstract][Full Text] [Related]
5. The dual function of the MHC class II transactivator CIITA against HTLV retroviruses.
Tosi G; Bozzo L; Accolla RS
Front Biosci (Landmark Ed); 2009 Jan; 14(11):4149-56. PubMed ID: 19273341
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y.
Tosi G; Pilotti E; Mortara L; De Lerma Barbaro A; Casoli C; Accolla RS
Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12861-6. PubMed ID: 16908858
[TBL] [Abstract][Full Text] [Related]
7. Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication.
Orlandi C; Forlani G; Tosi G; Accolla RS
J Transl Med; 2011 Jul; 9():106. PubMed ID: 21736733
[TBL] [Abstract][Full Text] [Related]
8. Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses.
Forlani G; Accolla RS
Front Immunol; 2017; 8():1362. PubMed ID: 29093716
[TBL] [Abstract][Full Text] [Related]
9. The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2.
Casoli C; De Lerma Barbaro A; Pilotti E; Bertazzoni U; Tosi G; Accolla RS
Blood; 2004 Feb; 103(3):995-1001. PubMed ID: 14525769
[TBL] [Abstract][Full Text] [Related]
10. The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells.
Forlani G; Turrini F; Ghezzi S; Tedeschi A; Poli G; Accolla RS; Tosi G
J Transl Med; 2016 Apr; 14():94. PubMed ID: 27089879
[TBL] [Abstract][Full Text] [Related]
11. The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy.
Forlani G; Shallak M; Gatta A; Shaik AKB; Accolla RS
Biomed J; 2023 Oct; 46(5):100631. PubMed ID: 37467968
[TBL] [Abstract][Full Text] [Related]
12. Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1.
Forlani G; Tosi G; Turrini F; Poli G; Vicenzi E; Accolla RS
Front Immunol; 2017; 8():564. PubMed ID: 28555140
[TBL] [Abstract][Full Text] [Related]
13. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
14. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
[TBL] [Abstract][Full Text] [Related]
15. p30 protein: a critical regulator of HTLV-1 viral latency and host immunity.
Moles R; Sarkis S; Galli V; Omsland M; Purcell DFJ; Yurick D; Khoury G; Pise-Masison CA; Franchini G
Retrovirology; 2019 Dec; 16(1):42. PubMed ID: 31852501
[TBL] [Abstract][Full Text] [Related]
16. SAMHD1 host restriction factor: a link with innate immune sensing of retrovirus infection.
Sze A; Olagnier D; Lin R; van Grevenynghe J; Hiscott J
J Mol Biol; 2013 Dec; 425(24):4981-94. PubMed ID: 24161438
[TBL] [Abstract][Full Text] [Related]
17. HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ.
Giam CZ; Semmes OJ
Viruses; 2016 Jun; 8(6):. PubMed ID: 27322308
[TBL] [Abstract][Full Text] [Related]
18. Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors.
van Montfoort N; Olagnier D; Hiscott J
Cytokine Growth Factor Rev; 2014 Dec; 25(6):657-68. PubMed ID: 25240798
[TBL] [Abstract][Full Text] [Related]
19. Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis.
Olière S; Douville R; Sze A; Belgnaoui SM; Hiscott J
Cytokine Growth Factor Rev; 2011 Aug; 22(4):197-210. PubMed ID: 21924945
[TBL] [Abstract][Full Text] [Related]
20. Friend retrovirus studies reveal complex interactions between intrinsic, innate and adaptive immunity.
Dittmer U; Sutter K; Kassiotis G; Zelinskyy G; Bánki Z; Stoiber H; Santiago ML; Hasenkrug KJ
FEMS Microbiol Rev; 2019 Sep; 43(5):435-456. PubMed ID: 31087035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
